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An etiological role of high risk human papillomavirus (HPV) in the development of cervical cancer has been well established. Hence, 
attention of researchers has been focused on the role of HPV in pathogenesis of other malignancies, such as head and neck cancers. 
An analysis of epidemiological data on the prevalence of HPV infection among healthy people and patients with precancerous lesions 
and/or cancer is an important step in understanding the role of HPV in head and neck carcinogenesis. More and more data de­
monstrate the impact of HPV infection on disease outcome. HPV­positive patients have been shown to have better responses 
to radiotherapy and better overall and disease­free survival than HPV­negative patients. This review presents data of the meta­
analysis based on a large number of original studies on HPV prevalence in patients with precancerous lesions and in patients with 
oral, oropharyngeal and laryngeal cancers as well as findings on the impact of HPV infection on survival of these patients.
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Members of the Papillomaviridae family play 
an important role in the development of certain types 
of human malignancies, such as oropharyngeal and 
anogenital cancers [1, 2]. Head and neck cancer (HNC) 
is the fifth most common type of cancer and the sixth 
most common cause of cancer death worldwide. About 
550,000 new cases are reported worldwide annually [3].
The HPV involvement in oral and oropharyngeal 
carcinogenesis was suggested based on viral tropism 
to the epithelial cells and oncogenic potential of high 
risk HPV genotypes in the pathogenesis of anogenital 
neoplasia, particularly in cervical squamous cell car-
cinoma and the morphological similarities between 
oropharyngeal and genital epithelia [4–9].
Almost 90% of HNC cases are of squamous epithe-
lial cell origin that could be characterized by a multistep 
and multifactorial pathogenesis [10–12]. It has been 
shown that besides smoking and alcohol use, some 
infectious pathogens, such as human papillomavirus 
(HPV) may act as a carcinogenic factor for HNC of cer-
tain locations, particularly the oropharynx [13, 14].
To evaluate the etiological role of HPV, it is impor-
tant to understand whether the prevalence of HPV 
DNA become higher during malignant transformation 
of normal epithelium to dysplasia, then to carcinoma 
in situ and finally to invasive cancer. A large amount 
of the data giving evidence of HPV DNA in head and 
neck squamous cell carcinoma (HNSCC) has been ac-
cumulated and a systematic review and meta-analyses 
of these data should be performed. Since most of the 
original studies were conducted using small number 
of samples, the meta-analysis is an effective statistical 
tool, which depends less on specific initial data than 
on each study individually, thus solving the problem 
of low statistical power of each individual study.
It should be noted that each meta-analysis de-
termines its own inclusion criteria; therefore, the 
 following results of evaluation are rather complemen-
tary than contradictory and allow the studied problem 
to be described more adequately. The meta-analyses, 
described in the present article are mainly focused 
on the following points:
•	prevalence of HPV in HNSCC tissues, which is ex-
pressed as a percentage, usually with 95% confi-
dence interval (CI);
•	the odds ratio (OR) — the ratio of the probability 
of presence the studied risk factors in the HPV-
positive patients compared with HPV-negative ones;
•	survival of HPV-positive patients. Typically, the surviv-
al rate is estimated, using the Kaplan — Meier analysis 
and it is quantitatively assessed as a percentage 
survival of each group or calculated risk ratio of ad-
verse outcome (hazard ratio — HR) in the presence 
of HPV-infection. The lower HR value, the difference 
in survival between HPV-positive and HPV-negative 
patients is higher.
The main aim of this review was to summarize all 
certain segments of available information with the 
focus on infection prevalence, risk of HPV-associated 
HNC, and also progression and survival of virus-
positive and virus-negative individuals.
The prevalence of HPV in head and neck pre-
cancerous lesions. There are two types of precan-
cerous lesions in the oral cavity mucosa: leukoplakia 
and erythroplakia [15]. Based on published data [2], 
the incidence of HPV DNA in leukoplakia was 31.1% 
(300/964 cases). The predominant HPV types were 
HPV-6 and HPV-11 (HPV-6/-11, 55.8%) followed 
by HPV-16/-18 (28.2%). Only a few cases of erythro-
plakia have been described in the literature. The au-
thors reported on 32 cases of erythroplakia, 9 of them 
had HPV-16 DNA. In addition, Nielsen et al. [16] de-
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scribed 10 cases with erythroplakia, 50% of them being 
HPV-positive. The prevalence of HPV-16/-18 in oral 
cavity and oropharyngeal dysplasia (OOPD) has been 
recently shown [17].
The meta-analysis was performed using the results 
of 22 studies that reported prevalence of  HPV-16 and/or 
-18 in 458 OOPD cases. The overall prevalence of HPV-
16/-18 in OOPD lesions was 24.5% (95% CI 16.4–36.7). 
The individual prevalence for  HPV-16 alone was 24.4%. 
The prevalence of HPV-16/-18 in oral cavity lesions 
was 25.3% (95% CI 14.2–45.2). The odds of HPV-
16/-18 detection in dysplastic lesions in males were 
twice that of females (OR 2.44). HPV-16/-18 were 
3-fold more frequent in dysplastic lesions (OR 3.29; 
95% CI 1.95–5.53) and invasive cancers (OR 3.43; 
95% CI 2.07–5.69), than in normal tissue samples. 
There were no significant differences in the incidence 
of HPV-16/-18 between patients with mild, moderate 
and severe dysplastic changes.
Results of the presented meta-analysis support an as-
sumption that the HPV-16/-18 accumulation occurs in the 
early stage of oral and oropharyngeal carcinogenesis.
The prevalence of HPV in HNSCC. The high HPV 
prevalence in HNSCC explains the abundance of the 
reviews with the scope on a particular problem. Most 
of the studies took into account the specific anatomic 
sites and just very few of them has described HPV 
prevalence in HNSCC. The average of HPV prevalence 
in HNSCC was 21.9% [20], 25.9% [18], 34.5% [19], 
which is described in 3 meta-analyses performed 
on a cohort of about 5000 patients (Table 1).
Interestingly, the difference in HPV DNA prevalence 
is observed between the cohorts with similar  percentage 
of patients. It is likely to be caused by different inclusion 
criteria used in studies described above. Furthermore, 
the following points can also have a considerable effect: 
variety of methods used for HPV detection, different 
origin of patients, varying percentage of cases with par-
ticular cancer sites. Thus, there is a definite re quisite for 
stratification of HNC patient groups depending on the 
anatomical site of squamous cell carcinoma.
It was shown that HPV-16 is the most prevalent 
genotype among all HNSCCs (73.3% [18], 86.7% [20], 
82.5% [21]), followed by HPV-18 and -33 [18, 20]. 
Hobbs et al. [22] in a meta-analysis based on 17 studies 
with the total of 2012 patients, showed that HPV is most 
strongly associated with tonsillar cancer (OR 15.1; 95% 
CI 6.8–33.7), is intermediate for oropharyngeal cancer 
(OR 4.3; 95% CI 2.1–8.9), and is the weakest for oral 
cancer (OR 2.0; 95% CI 1.0–4.2).
It was also shown that HPV status was associ-
ated with p16 expression (adjusted OR 3.00; 95% 
CI 0.90–9.70; p = 0.18), and HPV-positive tumors were 
less likely to harbor p53 mutations (adjusted OR 0.21; 
95% CI 0.04–0.38; p = 0.015) [20].
Survival rate of patients with HPV-positive and 
HPV-negative HNSCC cases was studied in three 
meta-analyses, and it was shown that HPV-positive 
patients had better prognosis: HR for overall survival 
(OS) was 0.42 [20], 0.46 [23], and 0.85 [24], and 
HR for disease-free survival (DFS) was 0.41 [23] and 
0.62 [24] (Table 2).
Table 1. HPV prevalence by different sites of HNC
State HPV prevalence (95% CI), % Study type N Source
Leukoplakia HPV-6/-11 — 55.8% Review 364 [2]
HPV-16/-18 — 28.2%
Erythroplakia HPV-16 — 28.1% 32
HPV — 50.0% Original study 10 [16]
Dysplasia HPV-16/-18 — 24.5% 
(16.4–36.7)
Meta-analysis 
of 22 studies
458 [17]
HNC Pooled HPV — 25.9% 
(24.7–27.2)
Meta-analysis 
of 60 studies
5046 [18]
Pooled HPV — 34.5% 
(28.4–40.6)
Meta-analysis 
of 62 studies
4852 [19]
Pooled HPV — 21.9% 
(21.0–23.0)
Meta-analysis 
of 34 studies
5681 [20]
HPV-16 — 86.7% 
(85.0–89.0)
Meta-analysis 
of 34 studies
5681 [20]
HPV-16 — 82.4% Meta-analysis 
of 269 studies
13972 [21]
HPV-16 — 73.3% Meta-analysis 
of 60 studies
5046 [18]
Oral cancer Pooled HPV — 23.5% 
(21.9–25.1)
Meta-analysis 
of 35 studies
2642 [18]
Pooled HPV — 38.1% 
(30.0–46.2)
Meta-analysis 
of 47 studies
3238 [19]
HPV-16 — 68.2% Meta-analysis 
of 35 studies
2642 [18]
Oropharyn-
geal cancer
Pooled HPV — 35.6% 
(32.6–38.7)
Meta-analysis 
of 27 studies
969 [18]
Pooled HPV — 47.7% 
(42.9–52.3)
Meta-analysis 
of 269 studies
5396 [21]
Pooled HPV — 63.8% Original study 323 [28]
HPV-16 — 86.7% Meta-analysis 
of 27 studies
969 [18]
HPV-16 — 96.1% Original study 323 [28]
Laryngeal 
cancer
Pooled HPV — 24.0% 
(21.8–26.3)
Meta-analysis 
of 35 studies
1435 [18]
Pooled HPV — 28.0% 
(23.5–32.9)
Meta-analysis 
of 55 studies
2559 [34]
HPV-16 — 69.2% Meta-analysis 
of 35 studies
1435 [18]
HPV-16 — 19.8% 
(15.7–24.6)
Meta-analysis 
of 55 studies
2559 [34]
The prevalence of HPV in oral cancer. Several 
meta-analyzes demonstrated the prevalence of HPV 
in the oral cancer [18, 19, 23]. According to these 
data, the HPV prevalence in oral cancer was ap-
proximately the same as in other HNC sites (23.5%). 
Other data demonstrate much higher prevalence 
(38.1% of cases). HPV-16 was detected in 68.2% and 
 HPV-18 in 34.1% (see Table 1).
The pooled HR for oral cancer was 0.32 (95% 
CI 0.16–0.68), that is mean, the OS rate in HPV-positive 
patients was 3 times higher than in HPV-negative ones 
(see Table 2).
The prevalence of HPV in oropharyngeal can-
cer. An independent population-based study in the 
United States (n = 271) showed that the population-
level incidence of HPV-positive oropharyngeal cancers 
increased by 225% from 1984 to 2004 (from 0.8 per 
100,000 to 2.6 per 100,000), and incidence for HPV-
negative cancers declined by 50% [25]. It is estimated 
that by 2020, the annual number of HPV-positive oro-
pharyngeal cancers will exceed the annual number 
of cervical cancers.
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In the meta-analysis of Kreimer et al. [18], the fre-
quency of HPV detection was significantly higher in oro-
pharyngeal cancer (35.6% of 969 cases) compared 
to oral cancer (23.5% of 2642 cases) and laryngeal 
cancer (24.0% of 1435 cases). HPV-16 was detected 
in 86.7% of patients with oropharyngeal cancer and 
HPV-18 in 2.8% of patients (see Table 1).
Table 2. Impact of HPV-infection on survival rate of HNC patients
State Survival type Rate Study type N Source
HNC OS HR 0.42 Meta-analysis 
of 34 studies
5682 [20]
OS HR 0.46  
(0.37–0.57)
Meta-analysis 
of 32 studies
3575 [23]
DFS HR 0.41  
(0.27–0.64)
Meta-analysis 
of 16 studies
1422 [23]
OS HR 0.85  
(0.7–1.0)
Meta-analysis 
of 19 studies
1990 [24]
DFS HR 0.62  
(0.5–0.8)
Meta-analysis 
of 9 studies
626 [24]
Oral 
cancer
OS HR 0.32  
(0.16–0.68)
Meta-analysis 
of 2 studies
n/a [23]
DFS HR 0.62  
(0.13–2.98)
Meta-analysis 
of 3 studies
n/a [23]
Oropha-
ryngeal 
cancer
OS HR 0.72  
(0.5–1.0)
Meta-analysis 
of 4 studies
224 [24]
DFS HR 0.51  
(0.4–0.7)
Meta-analysis 
of 5 studies
293 [24]
OS HR 0.47  
(0.35–0.62)
Meta-analysis 
of 17 studies
n/a [23]
DFS HR 0.37  
(0.22–0.63)
Meta-analysis 
of 8 studies
n/a [23]
3-year OS 
(HPV-positive 
vs HPV-nega-
tive), %
82.4 (77.2–87.6) 
vs 57.1  
(48.1–66.1)
Original study 323 [28]
3-year pro-
gression-
free survival 
(HPV-positive 
vs HPV-nega-
tive), %
73.7 (67.7–79.8) 
vs 43.4 
(34.4–52.4)
Original study 323 [28]
n/a — not available.
A meta-analysis of Mehanna et al. [21] based 
on 269 studies (1970–2008) included 5396 patients 
with oropharyngeal cancer and 13,972 patients with 
non-oropharyngeal cancer. The overall pooled HPV 
prevalence in patients with oropharyngeal cancer was 
47.7% (95% CI 42.9–52.5). Overall HPV prevalence 
in oropharyngeal cancer increased significantly over 
time in Europe (p < 0.004) and in North America (p < 
0.002) from 40.5% (95% CI 35.1–46.1) in the 54 stu-
dies that recruited patients before 2000 to 64.3% (95% 
CI 56.7–71.3) in cohorts recruited between 2000 and 
2004 (22 studies) and to 72.2% (95% CI 52.9–85.7) 
from 2004–2008 (4 studies) (see Table 1). These 
findings were consistent with the data obtained 
by Chaturvedi et al. [25]. Overall HPV prevalence dif-
fered by geographic region. The overall prevalence was 
35.3% in Europe, 50.7% in North America and 32.2% 
in all other regions (p = 0.008). For oropharyngeal can-
cer, HPV-16 was positive in 1353 (95.7%) of 1414 cases.
Overall HPV prevalence in non-oropharyngeal 
cancer was 21.8% (95% CI 18.9–25.1), and there ap-
peared to be statistically insignificant, declining trend 
over time. Thus, the pooled HPV prevalence was 22.2% 
before 2000 (95% CI 18.4–26.4), compared with 17.2% 
(95% CI 11.9–24.4) between 2000 and 2004 and 6.1% 
(95% CI 0.7–39) from 2004 to 2008. No statistically 
significant difference between the regions was found. 
The HPV-16 was detected in 1626 (73.9%) out of the 
2199 HPV-positive patients with oropharyngeal cancer.
Gillison et al. [26] reported that the major risk factors 
for HPV-positive oropharyngeal cancer are: high lifetime 
number of both oral and vaginal sexual partners, early 
age of sexual debut, anogenital warts and the con-
sumption of marijuana. HPV-negative oropharyngeal 
cancer is strongly associated with tobacco and alcohol 
consumption, older age and poor oral hygiene.
According to a meta-analysis of Ragin et al. [24], 
HPV-positive patients with oropharyngeal cancer had 
a 28% lower risk of dying compared with HPV-negative 
patients (HR 0.72; 95% CI 0.5–1.0) (see Table 2). Similar 
findings were published in a prospective analysis of data 
from clinical trials [27]. In order to evaluate other fa-
vorable prognostic factors associated with HPV status 
of the tumor, Ang et al. [28] analyzed survival rates 
of patients with oropharyngeal squamous cell carcinoma. 
A total of 63.8% of patients with oropharyngeal cancer 
(206 of 323) had HPV-positive tumors, and 198 (96.1%) 
of 206 were positive for HPV-16. Kaplan — Meier 
analysis revealed that HPV-positive cancer patients had 
better overall and DFS compared with HPV-negative 
patients (p < 0.001). 3-year OS was 82.4% (95% 
CI 77.2–87.6) in HPV-positive patients and 57.1% (95% 
CI 48.1–66.1) in HPV-negative patients. The 3-year DFS 
rates were 73.7% (95% CI 67.7–79.8) and 43.4% (95% 
CI 34.4–52.4), respectively.
In the multivariable analysis, the age, race, perfor-
mance status, tumor stage, nodal stage, and number 
of pack-years of tobacco smoking were also significant 
determinants of the OS and DFS.
Tumors were evaluated for the expression of not only 
HPV, but also for p16, a known biomarker of HPV infec-
tion. The presence of HPV and p16 expression in tumors 
were in good agreement (κ = 0.80; 95% CI 0.73–0.87). 
Using p16 expression as a stratification factor, the dif-
ferences in the OS and DFS rates, that were consistent 
with those based on HPV status, were shown. Thus, the 
3-year survival rate was 83.6% in patients with p16-
positive expression and 51.3% (95% CI 41.5–61.0) in the 
patients with p16-negative expression.
Recursive-partitioning analysis showed that the 
HPV status of the tumor was the major determinant 
of OS, followed by the number of pack-years of tobacco 
smoking and then nodal stage for HPV-positive tumors, 
or tumor stage for HPV-negative tumors.
In a meta-analysis by O’Rorke et al. [23], the au-
thors examined the difference in OS between the HPV-
positive and HPV-negative patients with oropharyngeal 
cancer and found that the pooled HR was 0.47 (95% 
CI 0.35–0.62) (see Table 2).
The prevalence of HPV in laryngeal cancer. In a me-
ta-analysis stratified by anatomical site,  Kreimer et al. [18] 
reported that the prevalence of HPV in laryngeal squamous 
cell carcinomas was 24.0% (of a total of 1435 cases) 
and found HPV-16 positivity in 69.2% of cases and HPV-
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18 positivity in 17.0% of ca ses. Meta-analysis by Tor-
rente et al. [29] demonstrated the same HPV prevalence 
(24.0%; 95% CI 21.8–26.3) in laryngeal cancer patients. 
The authors paid attention to the fact that the overall HPV 
prevalence in normal laryngeal mucosa was not deter-
mined because sampling methods for HPV detection 
in healthy cells were not standardized, and prevalence 
estimates remained inconsistent.
The reported incidence of HPV infection in normal 
laryngeal mucosa has been as high as 19.0% [30–33]. 
These results suggest that the number of HPV-positive 
cancers observed might reflect the prevalence of latent 
HPV infections in the vocal cord epithelium.
Li et al. [34] performed a systemic review and meta-
analysis based on 55 studies that tested the presence 
of HPV in laryngeal cancer patients. It was reported 
that HPV DNA was detected in 28.0% of the 2559 cases 
of laryngeal carcinoma (95% CI 23.5–32.9%) (see 
Table 1). The prevalence of high risk HPV types was 
significantly higher than that of low risk HPV types 
(26.6% vs 3.7%). The most common HPV type 
was HPV-16, with a summary prevalence of 19.8% 
(95% CI 15.7–24.6). The remaining most frequently 
identified HPV types were HPV-18 (6.2% of cases; 
95% CI 4.0–9.5), HPV-33 (3.3%; 95% CI 2.1–5.1), 
HPV-31 (2.4%; 95% CI 1.3–4.4), HPV-6 (4.3%; 95% 
CI 2.4–7.7) and HPV-11 (2.3%; 95% CI 1.2–4.4).
Analyses stratified by cancer location showed 
that laryngeal cancers in the glottis region had the 
highest HPV prevalence (35.2%; 95% CI 28.2–42.8), 
followed by those in the supraglottic region (30.5%; 
95% CI 24.0–37.8) and the subglottic region (27.5%; 
95% CI 17.5–40.4). The microenvironment of the 
glottis might favor HPV infection, because the squa-
mocolumnar junction in the ventricle is similar to the 
cervical transformation zone.
The estimated HPV prevalence among laryngeal 
cancers might vary with respect to the analyzed popu-
lation, HPV detection methods and tumor charac-
teristics. The prevalence of high risk HPV was found 
to be much higher than that of low risk HPV types.
Various HPV prevalences in laryngeal cancers were 
observed in different geographical regions (range; 
25.6–35.6%). Studies from South America reported 
a higher rate of HPV infection compared with that ob-
served in Asia, North America and Europe.
In a meta-analysis based on 12 case-control studi es, 
Li et al. [34] estimated the association between HPV infec-
tion and the risk of laryngeal cancer. A total of 638 patients 
with laryngeal cancer and 419 controls were enrolled. 
It was shown that HPV infection significantly increased 
the risk of laryngeal cancer (OR 5.39; 95% CI 3.25–8.94), 
this OR was higher than that for oropharyngeal cancer 
(OR 4.3; 95% CI 2.1–8.9) and oral cancer (OR 2.0; 95% 
CI 1.2–3.4) demonstrated by Hobbs et al. [22].
The OR of individual types indicated diffe rences 
in the magnitudes of the association for HPV-
16 (6.07; 95% CI 3.44–10.7) and HPV-18 (4.16; 95% 
CI 1.87–20.04). For low risk HPV (16 and 11 types) the 
OR were not statistically significant.
When estimating survival, O’Rorke et al. [23] 
showed that patients with HPV-positive laryngeal squa-
mous cell carcinoma had a 50% lower risk of mortality 
compared to HPV-negative patients (HR 0.5; 95% 
CI 0.33–0.77) (see Table 2).
CONCLUSION 
The prevalence of HPV was found to be greater 
in HNC than in dysplasia and HPV virus was most 
frequently detected in oropharyngeal cancer among 
the different anatomical sites, HPV-16 was the most 
prevalent HPV type in HNC.
In spite of tumor location, the risk of dying was 
lower and survival was higher in HPV-positive patients 
than in HPV-negative patients, indicating that along 
with the carcinogenic effect, HPV is able to modulate 
the disease and influence on the prognosis.
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